These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 34470724)

  • 1. First-line chemotherapy with raltitrexed in metastatic colorectal cancer: an Association des Gastro-entérologues Oncologues (AGEO) multicentre study.
    Gallois C; Hafliger E; Auclin E; Perret A; Coutzac C; Turpin A; Pellat A; Randrian V; Basile D; Faroux R; Pernot S; Locher C; Hautefeuille V; Dubreuil O; Palmieri LJ; Dior M; Artru P; Taieb J
    Dig Liver Dis; 2022 May; 54(5):684-691. PubMed ID: 34470724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab Combined with S-1 and Raltitrexed for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies: A Phase II Study.
    Chen Y; Zhou YW; Cheng K; Li ZP; Luo DY; Qiu M; Li Q; Wang X; Shen YL; Cao D; Yang Y; Bi F; Liu JY; Gou HF
    Oncologist; 2021 Aug; 26(8):e1320-e1326. PubMed ID: 33830591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.
    Ghiringhelli F; Vincent J; Bengrine L; Borg C; Jouve JL; Loffroy R; Guiu B; Blanc J; Bertaut A
    J Cancer Res Clin Oncol; 2019 Sep; 145(9):2357-2363. PubMed ID: 31273511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of raltitrexed-based first-line chemotherapy in advanced colorectal cancer.
    Barni S; Ghidini A; Coinu A; Borgonovo K; Petrelli F
    Anticancer Drugs; 2014 Nov; 25(10):1122-8. PubMed ID: 24869761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial.
    Cheng K; Zhou YW; Chen Y; Li ZP; Qiu M; Liu JY
    Cancer Control; 2022; 29():10732748221080332. PubMed ID: 35343258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Raltitrexed plus oxaliplatin (TOMOX) as first-line chemotherapy for metastatic colorectal cancer. A phase II study of the Italian Group for the Study of Gastrointestinal Tract Carcinomas (GISCAD).
    Cascinu S; Graziano F; Ferraù F; Catalano V; Massacesi C; Santini D; Silva RR; Barni S; Zaniboni A; Battelli N; Siena S; Giordani P; Mari D; Baldelli AM; Antognoli S; Maisano R; Priolo D; Pessi MA; Tonini G; Rota S; Labianca R
    Ann Oncol; 2002 May; 13(5):716-20. PubMed ID: 12075739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer.
    Batra A; Rigo R; Hannouf MB; Cheung WY
    Clin Colorectal Cancer; 2021 Jun; 20(2):e75-e81. PubMed ID: 33268287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial.
    Chen Y; Wu J; Cheng K; Li ZP; Luo DY; Qiu M; Gou HF; Yi C; Li Q; Wang X; Yang Y; Cao D; Shen YL; Bi F; Liu JY
    Oncologist; 2019 May; 24(5):591-e165. PubMed ID: 30651398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial chemoembolization with raltitrexed-based or floxuridine-based chemotherapy for unresectable colorectal cancer liver metastasis.
    Wei N; Zhang B; Wang Y; He XH; Xu LC; Li GD; Wang YH; Wang GZ; Huang HZ; Li WT
    Clin Transl Oncol; 2019 Apr; 21(4):443-450. PubMed ID: 30306400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy.
    Scheithauer W; Kornek GV; Schuell B; Ulrich-Pur H; Penz M; Raderer M; Lang F; Schneeweiss B; Lenauer A; Depisch D
    Ann Oncol; 2001 May; 12(5):709-14. PubMed ID: 11432632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II randomised trial of raltitrexed-oxaliplatin vs raltitrexed-irinotecan as first-line treatment in advanced colorectal cancer.
    Feliu J; Castañón C; Salud A; Mel JR; Escudero P; Pelegrín A; López-Gómez L; Ruiz M; González E; Juárez F; Lizón J; Castro J; González-Barón M;
    Br J Cancer; 2005 Nov; 93(11):1230-5. PubMed ID: 16265344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.
    Khan K; Rane JK; Cunningham D; Rao S; Watkins D; Starling N; Kalaitzaki E; Forster M; Braconi C; Valeri N; Gerlinger M; Chau I
    Clin Colorectal Cancer; 2019 Mar; 18(1):64-71.e1. PubMed ID: 30404764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic artery infusion with raltitrexed or 5-fluorouracil for colorectal cancer liver metastasis.
    Guo JH; Zhang HY; Gao S; Zhang PJ; Li XT; Chen H; Wang XD; Zhu X
    World J Gastroenterol; 2017 Feb; 23(8):1406-1411. PubMed ID: 28293087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Raltitrexed and oxaliplatin in colorectal cancer: in vitro and in vivo study of a synergistic cytostatic combination].
    Schüll B; Scheithauer W
    Acta Med Austriaca; 2002; 29(4):124-31. PubMed ID: 12424937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of raltitrexed combinations with uracil- tegafur or mitomycin C as salvage treatment in advanced colorectal cancer patients: a multicenter study of Anatolian Society of Medical Oncology (ASMO).
    Bozkurt O; Karaca H; Ciltas A; Kaplan MA; Benekli M; Sevinc A; Demirci U; Eren T; Kodaz H; Isikdogan A; Ozkan M; Buyukberber S
    Asian Pac J Cancer Prev; 2014; 15(4):1845-9. PubMed ID: 24641419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice.
    Dinu IM; Mihăilă M; Diculescu MM; Croitoru VM; Turcu-Stiolica A; Bogdan D; Miron MI; Lungulescu CV; Alexandrescu ST; Dumitrașcu T; Buică F; Luca IN; Lungulescu C; Negulescu MC; Gramaticu IM; Cazacu IM; Croitoru AE
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837551
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
    Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R
    Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Raltitrexed-based chemotherapy for advanced colorectal cancer.
    Liu Y; Wu W; Hong W; Sun X; Wu J; Huang Q
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):219-25. PubMed ID: 24388340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.